EP2500337A3 - Formes solides comprenant du (-)-O-desméthylvenlafaxine et leurs utilisations - Google Patents

Formes solides comprenant du (-)-O-desméthylvenlafaxine et leurs utilisations Download PDF

Info

Publication number
EP2500337A3
EP2500337A3 EP12164795A EP12164795A EP2500337A3 EP 2500337 A3 EP2500337 A3 EP 2500337A3 EP 12164795 A EP12164795 A EP 12164795A EP 12164795 A EP12164795 A EP 12164795A EP 2500337 A3 EP2500337 A3 EP 2500337A3
Authority
EP
European Patent Office
Prior art keywords
disorders
desmethylvenlafaxine
prevention
management
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12164795A
Other languages
German (de)
English (en)
Other versions
EP2500337A2 (fr
Inventor
Michael Sizensky
Harold S. Wilkinson
John Snoonian
Norman Kim
Sharon M. Laughlin
Roger P. Bakale
Kevin Plunkett
Patrick Mousaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP2500337A2 publication Critical patent/EP2500337A2/fr
Publication of EP2500337A3 publication Critical patent/EP2500337A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EP12164795A 2007-02-21 2008-02-21 Formes solides comprenant du (-)-O-desméthylvenlafaxine et leurs utilisations Withdrawn EP2500337A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21
EP08725968.5A EP2114863B1 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-o-desmethylvenlafaxine et utilisations de celles-ci

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP08725968.5 Division 2008-02-21
EP08725968.5A Division-Into EP2114863B1 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-o-desmethylvenlafaxine et utilisations de celles-ci
EP08725968.5A Division EP2114863B1 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-o-desmethylvenlafaxine et utilisations de celles-ci

Publications (2)

Publication Number Publication Date
EP2500337A2 EP2500337A2 (fr) 2012-09-19
EP2500337A3 true EP2500337A3 (fr) 2012-12-26

Family

ID=39432564

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12164795A Withdrawn EP2500337A3 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-O-desméthylvenlafaxine et leurs utilisations
EP08725968.5A Active EP2114863B1 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-o-desmethylvenlafaxine et utilisations de celles-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08725968.5A Active EP2114863B1 (fr) 2007-02-21 2008-02-21 Formes solides comprenant du (-)-o-desmethylvenlafaxine et utilisations de celles-ci

Country Status (18)

Country Link
US (2) US20090005457A1 (fr)
EP (2) EP2500337A3 (fr)
JP (1) JP5666140B2 (fr)
KR (1) KR101528326B1 (fr)
CN (1) CN101663263A (fr)
AR (1) AR065431A1 (fr)
AU (1) AU2008218997B2 (fr)
BR (1) BRPI0807604A2 (fr)
CA (1) CA2678599C (fr)
ES (1) ES2609264T3 (fr)
IL (1) IL200514A (fr)
MX (1) MX2009008705A (fr)
NZ (2) NZ599480A (fr)
RU (1) RU2477269C2 (fr)
SG (1) SG175611A1 (fr)
TW (1) TWI446903B (fr)
WO (1) WO2008103461A2 (fr)
ZA (1) ZA200905698B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2142183A2 (fr) * 2007-04-09 2010-01-13 Sepracor Inc. Procédés et compositions destinées au traitement de troubles respiratoires liés au sommeil
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ302145B6 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
US20120263838A1 (en) * 2011-04-12 2012-10-18 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
WO2018146529A1 (fr) * 2017-02-09 2018-08-16 R L Finechem Private Limited Procédé de préparation de 1-[2-(diméthylamino)-1-(4-hydroxyphényl) éthyl]-cyclohexanol et de ses sels
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法
US12227566B2 (en) 2018-12-05 2025-02-18 Hedgehog, Inc. Endothelin receptor type a activity regulating antibody
WO2021243351A2 (fr) * 2020-05-26 2021-12-02 Mars, Incorporated Procédé de préparation d'aliments pour animaux de compagnie et aliment pour animaux de compagnie pouvant être obtenu selon ce procédé
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076955A1 (fr) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomeres de o-desmethyl venlafaxine
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US20030236309A1 (en) * 2002-06-10 2003-12-25 Wyeth Novel formate salt of O-desmethyl-venlafaxine
WO2007005961A2 (fr) * 2005-07-06 2007-01-11 Sepracor Inc. Combinaisons d'un eszopiclone et d'un o-desmethylvenlafaxine, et methodes de traitement de la menopause et de l'humeur, de l'anxiete et des troubles cognitifs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US20060199860A1 (en) * 1998-12-01 2006-09-07 Jerussi Thomas P Salts of (-)-O-desmethylvenlafaxine
WO2000076955A1 (fr) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomeres de o-desmethyl venlafaxine
US20030236309A1 (en) * 2002-06-10 2003-12-25 Wyeth Novel formate salt of O-desmethyl-venlafaxine
WO2007005961A2 (fr) * 2005-07-06 2007-01-11 Sepracor Inc. Combinaisons d'un eszopiclone et d'un o-desmethylvenlafaxine, et methodes de traitement de la menopause et de l'humeur, de l'anxiete et des troubles cognitifs

Also Published As

Publication number Publication date
ES2609264T3 (es) 2017-04-19
TW200901955A (en) 2009-01-16
EP2114863A2 (fr) 2009-11-11
ZA200905698B (en) 2010-10-27
EP2114863B1 (fr) 2016-10-05
TWI446903B (zh) 2014-08-01
WO2008103461A3 (fr) 2008-11-13
AU2008218997A1 (en) 2008-08-28
RU2477269C2 (ru) 2013-03-10
AR065431A1 (es) 2009-06-10
NZ599480A (en) 2013-10-25
JP2010519300A (ja) 2010-06-03
MX2009008705A (es) 2009-09-10
US20090005457A1 (en) 2009-01-01
BRPI0807604A2 (pt) 2014-07-22
EP2500337A2 (fr) 2012-09-19
KR20090113904A (ko) 2009-11-02
IL200514A (en) 2013-12-31
RU2009135016A (ru) 2011-03-27
JP5666140B2 (ja) 2015-02-12
KR101528326B1 (ko) 2015-06-11
CA2678599A1 (fr) 2008-08-28
IL200514A0 (en) 2010-04-29
CA2678599C (fr) 2015-11-10
US20160355457A1 (en) 2016-12-08
CN101663263A (zh) 2010-03-03
AU2008218997B2 (en) 2013-06-20
NZ579137A (en) 2012-05-25
SG175611A1 (en) 2011-11-28
WO2008103461A2 (fr) 2008-08-28

Similar Documents

Publication Publication Date Title
EP2500337A3 (fr) Formes solides comprenant du (-)-O-desméthylvenlafaxine et leurs utilisations
WO2000059851A8 (fr) Derives de la venlafaxine et leurs procedes de preparation et utilisation
EP3252057A3 (fr) Composés multicycliques et leurs procédés d'utilisation
WO2009132656A3 (fr) Mise au point de ligands spécifiques de la sortiline
WO2010039186A3 (fr) Composés utiles en tant que modulateurs de la faah et leurs utilisations
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
WO2009110985A3 (fr) Composés amides, compositions à base de ces composés et leurs utilisations
IN2012DN02763A (fr)
WO2012088519A8 (fr) Compositions et procédés pour améliorer la fonction mitochondriale et traiter des maladies neurodégénératives et des troubles cognitifs
WO2007067495A3 (fr) Mésylate de promédicament de lévodopa, compositions comprenant celui-ci, et utilisations de celui-ci
BRPI0822111A2 (pt) Uso de uma composição líquida na fabricação de uma composição para prevenir e/ou tratar declínio da memória e/ou da disfunção cognitiva, mal de alzheimer, mal de parkinson e/ou demência, composição líquida, e, composição nutricional
WO2009117515A3 (fr) Nouveaux composés servant à traiter les maladies et troubles du système nerveux central
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
WO2013142124A8 (fr) Formes solides d'un promédicament nucléotidique thiophosphoramidate
EP2862581A3 (fr) Procédés, composés, compositions et véhicules pour l'administration d'acide 3-amino-1-propanesulfonique
WO2009067493A3 (fr) Benzènes 1,3,5-trisubstitués pour le traitement de la maladie d'alzheimer et d'autres troubles
CA3241845A1 (fr) Composes
EP2065040A3 (fr) Compositions pharmaceutiques dérivées de sphingolipide
BR112014002859A2 (pt) purificação pós-processamento para produção de gama-butiro lactona
WO2011107812A3 (fr) Composition pharmaceutique stabilisée
MY146429A (en) 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e-]-[1,2,4]-triazolo-[1,5-c-]-pyrimidin-5-amine
WO2007129221A3 (fr) Compositions et méthodes destinées au traitement de troubles liés à l'agrégation des protéines
WO2008070311A3 (fr) Examen de profil de l'expression génique de la maladie de parkinson
WO2009001356A3 (fr) Dérivés de l'acyl-urée et utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2114863

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 215/64 20060101AFI20121122BHEP

Ipc: C07C 213/10 20060101ALI20121122BHEP

Ipc: A61P 25/00 20060101ALI20121122BHEP

Ipc: A61K 31/137 20060101ALI20121122BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAKALE, ROGER, P.

Inventor name: WILKINSON, HAROLD, S.

Inventor name: LAUGHLIN, SHARON, M.

Inventor name: SIZENSKY, MICHAEL

Inventor name: MOUSAW, PATRICK

Inventor name: SNOONIAN, JOHN

Inventor name: KIM, NORMAN

Inventor name: PLUNKETT, KEVIN

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/137 20060101ALI20121221BHEP

Ipc: A61P 25/00 20060101ALI20121221BHEP

Ipc: C07C 213/10 20060101ALI20121221BHEP

Ipc: C07C 215/64 20060101AFI20121221BHEP

17P Request for examination filed

Effective date: 20130626

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20131021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140503